Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03816332 | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers | active not recruiting | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06007690 | A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma(CoMpass) | active not recruiting | Phase 3 | 108 | Aura BiosciencesINDUSTRY |
| 14 |
| Jul 31, 2026 |
| clinicaltrials |
| NCT07574047 | MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma. | not yet recruiting | Phase 2 | 108 | Swiss Cancer InstituteOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07628634 | Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors | recruiting | Early Phase 1 | 25 | University of California, IrvineOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT02718066 | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 96 | HUYABIO International, LLC.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04996823 | Axitinib + Ipilimumab in Advanced Melanoma | active not recruiting | Phase 2 | 24 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07634380 | Sitagliptin With Pembro in RCC and Melanoma | recruiting | Phase 1 | 64 | Fernando Maciel BarbosaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT01587352 | Vorinostat in Treating Patients With Metastatic Melanoma of the Eye | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jul 29, 2026 | clinicaltrials |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | recruiting | Phase 1 / Phase 2 | 340 | Inhibrx Biosciences, IncINDUSTRY | 4 | Jul 29, 2026 | clinicaltrials |
| NCT06081920 | A Study of IBI363 in Subjects With Advanced Melanoma | recruiting | Phase 2 | 180 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07680452 | Clinical Study on High-fiber Diet and Short-term Fasting in Melanoma Under Immunotherapy With Checkpoint Inhibition(Melafit) | recruiting | N/A | 60 | Charite University, Berlin, GermanyOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05282901 | Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)(PLUME) | completed | Phase 2 | 51 | Institut CurieOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05373823 | MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors | recruiting | N/A | 385 | Rutgers, The State University of New JerseyOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05415072 | A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | active not recruiting | Phase 1 / Phase 2 | 66 | Novartis PharmaceuticalsINDUSTRY | 7 | Jul 28, 2026 | clinicaltrials |
| NCT06150664 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | recruiting | Phase 1 | 85 | Compass TherapeuticsINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06627595 | Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management(APiTOXMM) | recruiting | — | 160 | University Hospital, MontpellierOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT00429312 | A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma | completed | Phase 1 / Phase 2 | 10 | Jennerex BiotherapeuticsINDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT03178123 | The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery | terminated | Phase 2 | 6 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT03417739 | A Phase II Study of BVD-523 in Metastatic Uveal Melanoma | terminated | Phase 2 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07518043 | A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors | recruiting | Phase 1 | 174 | Shanghai Henlius BiotechINDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07686835 | Dietary Fiber to Induce Gut Microbiota-mediated Response to Immunotherapy in Melanoma.(FIGURE-IM) | recruiting | Phase 2 | 70 | Radboud University Medical CenterOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT03915678 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors(AGADIR) | active not recruiting | Phase 2 | 247 | Institut BergoniéOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07042243 | The Florida ASCENT Study | recruiting | N/A | 100 | University of FloridaOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT02298959 | Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | active not recruiting | Phase 1 | 59 | National Cancer Institute (NCI)NIH | 2 | Jul 22, 2026 | clinicaltrials |
| NCT05098210 | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer | recruiting | Phase 1 | 28 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06666634 | Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy(NANOSCAN) | completed | N/A | 29 | The Netherlands Cancer InstituteOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT01708941 | Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 88 | National Cancer Institute (NCI)NIH | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06626516 | Tebentafusp-tebn With LDT in Metastatic UM | recruiting | Phase 1 / Phase 2 | 109 | Thomas Jefferson UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07230613 | Neo-adjuvant Immunotherapy in Patients With Localized Melanoma(NEOREM-NEO-1) | recruiting | Phase 2 | 50 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03225365 | Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma(IMMUNONIVO) | completed | N/A | 5 | Hospices Civils de LyonOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03405155 | Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery | completed | Phase 2 | 26 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05704647 | Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06060613 | Safety and Efficacy of OBX-115 in Advanced Solid Tumors(Agni-01) | recruiting | Phase 1 / Phase 2 | 208 | Obsidian Therapeutics, Inc.INDUSTRY | 2 | Jul 16, 2026 | clinicaltrials |
| NCT03384836 | Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery | suspended | Phase 1 / Phase 2 | 47 | Roswell Park Cancer InstituteOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT04407247 | Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06264180 | VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] | recruiting | Phase 3 | 400 | Replimune, Inc.INDUSTRY | 7 | Jul 15, 2026 | clinicaltrials |
| NCT06307093 | Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms | completed | Phase 1 | 90 | R-PharmINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06320353 | Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma | completed | Phase 3 | 266 | R-PharmINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07389525 | Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study | not yet recruiting | Early Phase 1 | 80 | Indiana UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02724488 | Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies(SPECIAL) | completed | — | 14 | University Health Network, TorontoOTHER | 0 | Jul 14, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT04697576 | Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma | recruiting | Phase 1 | 36 | Carlo ContrerasOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06424626 | A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma | enrolling by invitation | Phase 1 | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06848088 | A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment | enrolling by invitation | Phase 2 | 48 | Regeneron PharmaceuticalsINDUSTRY | 2 | Jul 13, 2026 | clinicaltrials |
| NCT07631325 | Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma(MORALE-MM) | not yet recruiting | Phase 1 / Phase 2 | 28 | John KirkwoodOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07700121 | PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma(PICSTAT) | not yet recruiting | Early Phase 1 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04201223 | Family Lifestyles, Actions, and Risk Education Intervention: Version 2(FLARE) | completed | N/A | 752 | University of UtahOTHER | 1 | Jul 10, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 31, 2026source: clinicaltrials